Work

Next frontiers in CAR T-cell therapy

Year: 2016

Type: article

Abstract: Chimeric antigen receptor (CAR) T-cell therapy is entering a new era, transitioning from an experimental approach being tested in a handful of centers to a more mainstream and broadly investigated therapeutic platform with significant efforts directed towards commercial translation. CARs are synthetic receptors engineered and transduced into T cells to redirect T-cell cytotoxicity by recognition of cell surface antigens expressed on cancer cells.1,2 Ongoing innovations into the design and application of CAR T cells are aimed at improving antitumor potency and, at the same time, ensuring safety of this promising therapy.

Source: Molecular Therapy — Oncolytics

DOI: 10.1038/mto.2016.28

Authors: Christine E Brown, Prasad S Adusumilli

Institutions: City Of Hope National Medical Center, Beckman Research Institute, Memorial Sloan Kettering Cancer Center

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,900